SLC5A2 and myocardial infarction: Fluvastatin (FLV) belongs to the class of statin drugs, which is frequently prescribed to lower lipid levels and reduce the risk of cardiovascular disease such as stroke and myocardial infarction.1 Empagliflozin (EMP) is a specific sodium-glucose co-transporter 2 (SGLT2) inhibitor that has demonstrated significant benefits among individuals suffering from type 2 diabetes.2 The co-administration of SGLT2 inhibitors and statins is a common practice in patients with hyperlipidemia and type 2 diabetes.